34 completed. 34 Phase 2, 19 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 34 | Completed 34 |
| Phase 1 | 19 | Completed 19 |
| Phase 3 | 5 | Completed 5 |
Follow Cryosurgery: new trials by email Literature Review of Cryosurgery trials Research Report on Cryosurgery
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors Cryoablation Therapy, Nivolumab, Ipilimumab - Osteosarcoma, Ewing Sarcoma | Phase 2 | Completed | Children's National Research Institute | 5 | 2022-02-18 | 2025-01-01 |
| Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma cryoablation, Sintilimab, lenvatinib - Intrahepatic Cholangiocarcinoma | Phase 2 | Completed | Fudan University | 28 | 2021-08-24 | 2025-02-21 |
| Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma Pembrolizumab, Cryoablation, Avelumab - Metastatic Urothelial Carcinoma, Bladder Cancer | Phase 2 | Completed | Massachusetts General Hospital | 9 | 2021-06-04 | 2026-01-22 |
| Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma Ipilimumab, Cryoablation, Nivolumab - Soft Tissue Sarcoma | Phase 2 | Completed | Kristen Ganjoo | 30 | 2019-10-01 | 2023-12-12 |
| A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma Opdivo Injectable Product, Yervoy Injectable Product, Cytoxan - Metastatic Prostatic Adenocarcinoma | Phase 2 | Completed | Rampart Health, L.L.C. | 12 | 2019-06-28 | 2022-06-21 |
| Bioinformation Therapy for Intestinal Cancer Cancer ablation, Life information rehabilitation therapy - Advanced Intestinal Cancer | Phase 2 / Phase 3 | Completed | Fuda Cancer Hospital, Guangzhou | 120 | 2017-11-30 | 2019-01-25 |
| Bioinformation Therapy for Liver Cancer Cancer ablation, Life information rehabilitation therapy - Liver, Cancer of, Non-Resectable | Phase 2 / Phase 3 | Completed | Fuda Cancer Hospital, Guangzhou | 120 | 2017-09-02 | 2019-01-25 |
| Bioinformation Therapy for Lung Cancer Cancer ablation, Life information rehabilitation therapy - Small-cell Lung Cancer | Phase 2 / Phase 3 | Completed | Fuda Cancer Hospital, Guangzhou | 120 | 2017-09-02 | 2019-01-25 |
| Bioinformation Therapy for Breast Cancer Cancer ablation, Life information rehabilitation therapy - Advanced Breast Cancer | Phase 2 / Phase 3 | Completed | Fuda Cancer Hospital, Guangzhou | 120 | 2017-09-02 | 2019-01-25 |
| Bioinformation Therapy for Pancreatic Cancer Cancer ablation, Life information rehabilitation therapy - Unresectable Pancreatic Cancer | Phase 2 / Phase 3 | Completed | Fuda Cancer Hospital, Guangzhou | 120 | 2017-09-01 | 2019-01-25 |
| Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis - Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 11 | 2017-08-15 | 2026-05-04 |
| Safety and Efficiency of γδ T Cell Against Breast Cancer Cryosurgery , IRE surgery ,surgery, γδ T cells, γδ T cells/ Surgery - Breast Cancer | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 100 | 2017-06-15 | 2020-07-13 |
| Safety and Efficiency of γδ T Cell Against Lung Cancer Cryosurgery or IRE surgery, γδ T cell, γδ T cells/ A Cryosurgery or IRE - Lung Cancer | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 30 | 2017-06-15 | 2020-07-13 |
| Safety and Efficiency of γδ T Cell Against Liver Cancer Cryosurgery or IRE surgery, γδ T cell, γδ T cells/ A Cryosurgery or IRE - Liver Cancer | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 30 | 2017-06-15 | 2020-07-13 |
| AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer AlloStim, Cryoablation - Colorectal Cancer Metastatic | Phase 2 | Completed | Mirror Biologics, Inc. | 13 | 2016-09-01 | 2025-05-16 |
| A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE) - Biliary Tract Neoplasms, Liver Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 54 | 2016-07-05 | 2023-03-28 |
| Combination of Cryosurgery and NK Immunotherapy for Advanced Liver Cancer Cryosurgery, NK Immunotherapy - Secondary Malignant Neoplasm of Liver | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 30 | 2016-07-01 | 2019-09-12 |
| Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer Cryosurgery, NK immunotherapy - Metastatic Renal Cell Cancer | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 30 | 2016-07-01 | 2019-09-12 |
| Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer Cryosurgery, NK immunotherapy - Metastatic Esophageal Cancer | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 60 | 2016-07-01 | 2019-09-12 |
| Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer Cryosurgery, NK immunotherapy - Recurrent Tongue Cancer | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 30 | 2016-07-01 | 2019-09-12 |
Showing 20 of 34. Sign in to see all of them.
Liver Neoplasms (6) · Carcinoma, Hepatocellular (5) · Neoplasm Metastasis (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (3) · Colorectal Neoplasms (3) · Sarcoma (3) · Biliary Tract Neoplasms (2) · Cholangiocarcinoma (2) · Kidney Neoplasms (2) · Lung Neoplasms (2) · Melanoma (2) · Ovarian Neoplasms (2) · Bile Duct Neoplasms (1)
Fuda Cancer Hospital, Guangzhou (21) · National Cancer Institute (NCI) (2) · Barbara Ann Karmanos Cancer Institute (1) · Children's National Research Institute (1) · Eastern Cooperative Oncology Group (1) · Fudan University (1) · Kristen Ganjoo (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · Michael Har-Noy (1) · Mirror Biologics, Inc. (1) · Rampart Health, L.L.C. (1) · University of Colorado, Denver (1)
China (22) · United States (11) · Israel (1)
Jibing Chen, MD, PhD (7) · Guifeng Liu, PhD (3) · Jibing Chen, PhD (3) · Tim F Greten, M.D. (2) · AeRang Kim, MD, PhD (1) · David G Bostwick, M.D.,M.B.A. (1) · Dr. Michael Har-Noy (1) · Eric Wehrenberg-Klee, MD (1) · Greg V. Stiegmann, MD (1) · James L. Peacock, MD (1) · Kristen Ganjoo, MD (1) · Lizhi Niu, PhD (1) · Madappa Kundranda, MD PHD (1) · Peng Wang, MD (1) · Peter J. Littrup, MD (1)
PMID 27816492, PMID 28508945, PMID 28923358, PMID 30578687, PMID 30688989, PMID 38205877, PMID 39965889, PMID 41176543
P30CA022453 (1), P50CA097274 (1), R01CA219960 (1)